Last reviewed · How we verify
XC221
XC221 is a small molecule that inhibits the activity of the SARS-CoV-2 main protease.
XC221 is a small molecule that inhibits the activity of the SARS-CoV-2 main protease. Used for Treatment of COVID-19.
At a glance
| Generic name | XC221 |
|---|---|
| Sponsor | RSV Therapeutics LLC |
| Drug class | SARS-CoV-2 main protease inhibitor |
| Target | SARS-CoV-2 main protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
XC221 works by binding to the active site of the SARS-CoV-2 main protease, thereby preventing the cleavage of viral polyproteins and ultimately inhibiting viral replication. This mechanism of action is specific to the SARS-CoV-2 virus and is not expected to affect other proteases in the human body.
Approved indications
- Treatment of COVID-19
Common side effects
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections (PHASE3)
- A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19 (PHASE3)
- Study of the Effect of Food Intake on the Bioavailability of XC221 100 mg Tablets (PHASE1)
- A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19 (PHASE3)
- A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections (PHASE2)
- Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI (PHASE2)
- Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections (PHASE2)
- Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XC221 CI brief — competitive landscape report
- XC221 updates RSS · CI watch RSS
- RSV Therapeutics LLC portfolio CI